Exchange: NASDAQ·Updated 07:30 PM EST
ALZN logo

ALZN Alzamend Neuro Inc

$0.79
$0.2442
(23.94%)
Today
Closed $0.7758
$0.0142
(1.83%)
After Hours
Reported EarningsSep 16
Mkt Cap$3.74M
Vol93,305.00

About ALZN

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
38

Bearish Sentiment

How do you feel about ALZN?

UnforgivingTrader
$ALZN $1 stock with a $26 target by a verified wall st analyst..once people find this to will be too late to buy in under $4 🤫 $CHSN $RDAC $PARA.X $MERC watching these for momentum / short covering into market close
2
10
YogoMaster
$ALZN $ALZN checklist: ☑️ Cash > 2x market cap ☑️ ~37 months cash runway ☑️ Nasdaq compliance regained ☑️ S-1 withdrawn ☑️ Multiple Q4 catalysts ☑️ $26 analyst PT $5 then $10 short term
1
11
HustlerTV
Multiple Q4 catalyst with no dilution is a no brainer buy here near the 52 wk low $ALZN $MRNA long term adds
13
hiwatt
$ALZN Tuesday, October 27, 2026 222 notice Notice (Other) Tue 10/27 11:33 AM Joint NOTICE of Receipt by Alzamend Neuro, Inc. re 221 Order,, (Rivero, Andres) For those not familiar with the case, a final verdict could be handed down by years end. Five of the 6 charges Alzn filed against Biorsai have been allowed to continue for settlement by Judge Bloom. Alzn spent close to $2M on failed clinical trial and $2M on legal fees so far, so a favorable judgement for cost and damages could be north of $5M. With just 4.8M shares and no active ATM, a positive settlement could add over a dollar in value to the stock price.
1
10
StockfatherOG
$ALZN once compelling data releases it will see $3-$5+. A+ setup best I’ve seen in a while. Accumulating all dips.
12
AImoney78
$ALZN Market is valuing this below cash while multiple data readouts are approaching. Risk/reward looks heavily skewed in favor of bulls here.
10
BITCOINHYPE
$ALZN Ascendiant Capital initiated with a $26 PT ✅ Estimated $14.1M cash vs. just $6.2M market cap ✅ Only ~$1.14M quarterly burn = ~37 months of runway ✅ Regained Nasdaq compliance ✅ S-1 withdrawn, reducing near-term dilution concerns
10
christmastimeelf
$ALZN With only ~$1.14M quarterly burn, ALZN appears funded for years, has regained Nasdaq compliance, and recently withdrew its S-1, easing dilution fears. This should be 3-4X higher ALREADY!
9
hiwatt
$ALZN Patent---WO2026024717A1--REST avtivation and lithium salt administration for the treatment of neurological disorders-Jan 2026--inventor Harvard--funded NIH. The government has certain rights in this invention.
1
6
UnforgivingTrader
$ALZN $3 target by end of next week, $5 by end of the month. $LABT $SCAG $ZNB $AEHL keep eyes on these momentum plays for scalps
8
hiwatt
$ALZN What's different with this clinical trial and the stock this time compared to last year. 1- Actual bipolar patients compared to healthy individuals 2- 20 patients this time, only 6 in the lithium in the brain study 3-Both trials started in April, with completion last year on Nov 19th. This trial is estimated to complete in Dec. 4- For some reason, Alzn is holding their cards close this time. No 1st patient enrolled or 1st patient dosed PRs. Last year the stock went up 75% on 1st patient dosed news. 5- Last year the stock was trading in the $2 range, this year $1 range. 6-Last year institutions only owned 200K shares, this year 2.5M (52%) as of 11-5 7-This time Alzn has a better understanding of how the drug interacts within the brain and should be able to highlights those differences and benefits better. 8-Public is more aware of lithium benefits due to Harvard study, other trials for Alz have failed.
8
GMExAPE
$ALZN dont miss out ion the cheapies here before it gets data released. Everyone will be chasing AFTER it runs 100-200%..this price is golden here.. $ZNB $LABT $AEHL $ALPW top premarket movers on watch into open
8
YogoMaster
$ALZN amazing chart poised for continuatin over both major daily moving averages. lots of room to run and im ready
8
UnforgivingTrader
$ALZN should start gaining attraction soon. Still insanely hidden ! Scalping $CRIS $OMH $CMTG with this guy SL
8
GMExAPE
$ALZN 37 months cash runway with no dilution..this one could change lives especially when the news hits. Float is tiny!
5
DarknessAWAITz
$ALZN you know this is about to run big when the company removes the dilution risk through the S1
5
StockfatherOG
$ALZN cheapest biotech and most undervalued. Should grind higher rest of the year. $MRNA accumulating pullbacks for a longer hold. $MERC $PARA.X $RDAC keep eyes on dip buys for scalps into close.
4
Fuddsblood65
$ALZN Crooked fat slob Ault is about to implode this company with over 39 million resale shares! Massachusetts General Hospital has terminated is bipolar disorder study for lack of participants that meet the criteria for the study and the fda refuses to alter the study criteria to suit the study shortcomings
1
Jimroner
$ALZN are we bottomed out? If not, how low can it go? I generally think this is a stock worth accumulating for long term
1
EliteXTradeRoom
$ALZN I will check back in the 1.40s, too high up here unless it can breakout and stay above 1.62. Anything lower than 1.31, no entry. Target around 1.63 - 1.95
1

Advertisement|Remove ads.